{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:49:12Z","timestamp":1792756152627,"version":"4.5.0"},"reference-count":251,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1097\/ico.0b013e318201405a","type":"journal-article","created":{"date-parts":[[2011,3,9]],"date-time":"2011-03-09T15:11:00Z","timestamp":1299683460000},"page":"927-938","source":"Crossref","is-referenced-by-count":110,"title":["Treatments for Corneal Neovascularization: A Review"],"prefix":"10.1097","volume":"30","author":[{"given":"Deepak","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Illingworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210227","first-page":"19","article-title":"Leading causes of blindness worldwide.","volume":"283","author":"Roodhooft","year":"2002","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"R2-19-20210227","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: an epidemiologic review.","volume":"43","author":"Lee","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"R3-19-20210227","first-page":"38","article-title":"The etiology of ocular irritation in soft lens wearers: distribution in a large clinical sample.","volume":"4","author":"Roth","year":"1978","journal-title":"Contact Intraocul Lens Med J"},{"key":"R4-19-20210227","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00003226-199811000-00008","article-title":"Angiogenesis in corneal disease: histopathologic evaluation of 254 human corneal buttons with neovascularization.","volume":"17","author":"Cursiefen","year":"1998","journal-title":"Cornea"},{"key":"R5-19-20210227","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bjo.87.1.101","article-title":"Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation.","volume":"87","author":"Cursiefen","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R6-19-20210227","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1167\/iovs.07-0964","article-title":"Inhibition of corneal neovascularization by blocking the angiotensin type 1 receptor.","volume":"49","author":"Usui","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-19-20210227","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00003226-200304000-00021","article-title":"Corneal lymphangiogenesis: evidence, mechanisms and implications for corneal transplant immunology.","volume":"22","author":"Cursiefen","year":"2003","journal-title":"Cornea"},{"key":"R8-19-20210227","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1167\/iovs.03-0940","article-title":"Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis.","volume":"45","author":"Cursiefen","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R9-19-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198607033150110","article-title":"Advances in corneal transplantation.","volume":"315","author":"Lindstrom","year":"1986","journal-title":"N Engl J Med"},{"key":"R11-19-20210227","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0065-2776(08)60755-5","article-title":"Immune privilege and immune regulation in the eye.","volume":"48","author":"Niederkorn","year":"1990","journal-title":"Adv Immunol"},{"key":"R12-19-20210227","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.survophthal.2007.04.008","article-title":"Corneal graft rejection.","volume":"52","author":"Panda","year":"2007","journal-title":"Surv Ophthalmol"},{"key":"R13-19-20210227","first-page":"2148","article-title":"Fine needle diathermy occlusion of corneal vessels.","volume":"41","author":"Pillai","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-19-20210227","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization.","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R15-19-20210227","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature05249","article-title":"Corneal avascularity is due to soluble VEGF receptor-1.","volume":"443","author":"Ambati","year":"2006","journal-title":"Nature"},{"key":"R16-19-20210227","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1167\/iovs.02-0299","article-title":"FasL-Fas interactions regulate neovascularization in the cornea.","volume":"44","author":"Stuart","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R17-19-20210227","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1167\/iovs.05-1656","article-title":"Activation of CD36 inhibits and induces regression of inflammaotry corneal neovascularization.","volume":"47","author":"Mwaikambo","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R18-19-20210227","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.exer.2008.06.007","article-title":"Exacerbated corneal inflammation and neovascularization in the HO-2 null mice is ameliorated by biliverdin.","volume":"87","author":"Bellner","year":"2008","journal-title":"Exp Eye Res"},{"key":"R19-19-20210227","first-page":"264","article-title":"Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis and wound healing (an American Ophthalmological Society thesis).","volume":"104","author":"Azar","year":"2006","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R20-19-20210227","first-page":"1954","article-title":"Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization.","volume":"38","author":"BenEzra","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R21-19-20210227","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease.","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"R22-19-20210227","first-page":"222","article-title":"Spontaneous corneal neovascularization in nude mice: local imbalance between angiogenic and antiangiogenic factors.","volume":"34","author":"Kaminska","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R23-19-20210227","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1016\/S0021-9258(19)49853-0","article-title":"Angiogenesis.","volume":"267","author":"Folkman","year":"1992","journal-title":"J Biol Chem"},{"key":"R24-19-20210227","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0161-6420(95)30918-9","article-title":"Allograft conjunctival transplantation for bilateral ocular surface disorders.","volume":"102","author":"Kwitko","year":"1995","journal-title":"Ophthalmology"},{"key":"R25-19-20210227","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0039-6257(79)90020-1","article-title":"Neovasculogensis: triggering factors and possible mechanisms.","volume":"24","author":"BenEzra","year":"1979","journal-title":"Surv Ophthalmol"},{"key":"R26-19-20210227","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00003226-198501000-00008","article-title":"Experimental corneal neovascularization: biomicroscopic, angiographic and morphologic correlation.","volume":"4","author":"Burger","year":"1985","journal-title":"Cornea"},{"key":"R27-19-20210227","first-page":"253","article-title":"Corneal neovascularization.","volume":"1","author":"Cogan","year":"1962","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R28-19-20210227","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/00003226-199811000-00013","article-title":"In vivo confocal imaging of corneal neovascularization.","volume":"17","author":"Yayli","year":"1998","journal-title":"Cornea"},{"key":"R29-19-20210227","first-page":"2105","article-title":"The effect of total-body irradiation on corneal neovascularization in the Fischer 344 rat after chemical cauterization.","volume":"32","author":"Scroggs","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R31-19-20210227","first-page":"537","article-title":"An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal neovascularization. Comparison of experimental models of corneal neovascularization.","volume":"79","author":"Fromer","year":"1975","journal-title":"Am J Pathol"},{"key":"R32-19-20210227","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/BF02143072","article-title":"Enzyme activities in the rabbit cornea during immunogenic keratitis.","volume":"224","author":"van Haeringen","year":"1986","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R33-19-20210227","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0014-5793(01)02897-6","article-title":"Diminished corneal angiogenesis in gelatinase A-deficient mice.","volume":"508","author":"Kato","year":"2001","journal-title":"FEBS Lett"},{"key":"R34-19-20210227","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000055693","article-title":"Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularization.","volume":"33","author":"Ma","year":"2001","journal-title":"Ophthalmic Res"},{"key":"R35-19-20210227","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.exer.2004.08.023","article-title":"Delayed inflammation-associated corneal neovascularization in MMP-2-defiecient mice.","volume":"80","author":"Samolov","year":"2005","journal-title":"Exp Eye Res"},{"key":"R36-19-20210227","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00003226-200307000-00013","article-title":"Inhibition of corneal neovascularization by genetic ablation of CCR2.","volume":"22","author":"Ambati","year":"2003","journal-title":"Cornea"},{"key":"R37-19-20210227","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0076-6879(00)19034-2","article-title":"Solid mechanisms of photodynamic therapy-induced cell death.","volume":"319","author":"Ahmad","year":"2000","journal-title":"Methods Enzymol"},{"key":"R38-19-20210227","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1128\/JVI.75.20.9828-9835.2001","article-title":"Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.","volume":"75","author":"Zheng","year":"2001","journal-title":"J Virol"},{"key":"R39-19-20210227","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1001\/archopht.1981.03930010599002","article-title":"Clinical types of corneal transplant rejection: their manifestations, frequency, preoperative correlates, and treatment.","volume":"99","author":"Alldredge","year":"1981","journal-title":"Arch Ophthalmol"},{"key":"R40-19-20210227","first-page":"2485","article-title":"Loss and restoration of immune privilege in eyes with corneal neovascularization.","volume":"37","author":"Dana","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R41-19-20210227","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/eye.2008.308","article-title":"Biomarkers for corneal graft rejection?","volume":"23","author":"Hossain","year":"2009","journal-title":"Eye"},{"key":"R42-19-20210227","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0161-6420(94)31138-9","article-title":"Risk factors for corneal graft failure and rejection in the Collaborative Corneal Transplantation Studies.","volume":"101","author":"Maguire","year":"1994","journal-title":"Ophthalmology"},{"key":"R43-19-20210227","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00003226-198706040-00006","article-title":"Reducing the risk of corneal graft rejection. A comparison of different methods.","volume":"6","author":"Mayer","year":"1987","journal-title":"Cornea"},{"key":"R44-19-20210227","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3928\/1081-597X-19960101-24","article-title":"Risk factors for corneal graft failure.","volume":"12","author":"Price","year":"1996","journal-title":"J Refract Surg"},{"key":"R45-19-20210227","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.transproceed.2007.08.020","article-title":"Epidemiology and risk factors for corneal graft rejection.","volume":"39","author":"Sellami","year":"2007","journal-title":"Transplant Proc"},{"key":"R46-19-20210227","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/archopht.1992.01080220054021","article-title":"The Collaborative Corneal Transplantation Studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal tranplantation.","volume":"110","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"R47-19-20210227","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0161-6420(94)31376-5","article-title":"Cornea graft survival and visual outcome.","volume":"101","author":"Vail","year":"1994","journal-title":"Ophthalmology"},{"key":"R48-19-20210227","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/bjo.77.10.650","article-title":"Corneal transplantation in the United Kingdom and Republic of Ireland.","volume":"77","author":"Vail","year":"1993","journal-title":"Br J Ophthalmol"},{"key":"R49-19-20210227","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1442-9071.1986.tb00024.x","article-title":"Corneal graft survival: a retrospective Australian study.","volume":"14","author":"Bishop","year":"1986","journal-title":"Aust N Z J Ophthalmol"},{"key":"R50-19-20210227","first-page":"411","article-title":"The high-risk penetrating keratoplasty.","volume":"4","author":"Mader","year":"1991","journal-title":"Ophthalmol Clin North Am"},{"key":"R51-19-20210227","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1442-9071.1987.tb00300.x","article-title":"Hierarchy of prognostic factors for corneal allograft survival.","volume":"15","author":"Volker-Dieben","year":"1987","journal-title":"Aust N Z J Ophthalmol"},{"key":"R52-19-20210227","first-page":"604","article-title":"Corneal neovascularization after penetrating keratoplasty.","volume":"14","author":"Dana","year":"1995","journal-title":"Cornea"},{"key":"R53-19-20210227","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/bjo.86.9.945","article-title":"High risk corneal grafting.","volume":"86","author":"Hill","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"R54-19-20210227","first-page":"368","article-title":"Influence of pretransplant sensitization on the survival of corneal allografts.","volume":"23","author":"DAmaro","year":"1991","journal-title":"Transplant Proc"},{"key":"R55-19-20210227","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/eye.1995.48","article-title":"Immunosuppression in corneal transplantation.","volume":"9","author":"Hill","year":"1995","journal-title":"Eye"},{"key":"R56-19-20210227","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1442-9071.2007.01549.x","article-title":"Lymphangiogenesis concurrent with haemangiogenesis in the human cornea.","volume":"35","author":"Regina","year":"2007","journal-title":"Clin Exp Ophthalmol"},{"key":"R57-19-20210227","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s004170050106","article-title":"Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.","volume":"236","author":"Kruse","year":"1998","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R58-19-20210227","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/bjo.48.8.416","article-title":"Comparative study of the action of thiotepa and triamcinolone on corneal vascularization in rabbits.","volume":"48","author":"Lavergne","year":"1964","journal-title":"Br J Ophthalmol"},{"key":"R59-19-20210227","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/0002-9394(68)90821-0","article-title":"Prevention of corneal vascularization.","volume":"66","author":"Ey","year":"1968","journal-title":"Am J Ophthalmol"},{"key":"R60-19-20210227","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archopht.1967.00980020639013","article-title":"Cryotherapy in corneal vascularization.","volume":"77","author":"Mayer","year":"1967","journal-title":"Arch Ophthalmol"},{"key":"R61-19-20210227","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/archopht.1975.01010020797012","article-title":"Induced corneal vascularization remission with argon laser therapy.","volume":"93","author":"Reed","year":"1975","journal-title":"Arch Ophthalmol"},{"key":"R62-19-20210227","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/bjo.39.11.641","article-title":"Treatment of gross corneal opacificaiton by lamellar and annular lamellar keratoplasty.","volume":"39","author":"Leigh","year":"1955","journal-title":"Br J Ophthalmol"},{"key":"R63-19-20210227","first-page":"29","article-title":"Treatment of corneal vascularization by strontium 90 beta plaque.","volume":"13","author":"Ainslie","year":"1962","journal-title":"Clin Symp"},{"key":"R64-19-20210227","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0140-6736(61)90794-2","article-title":"Postoperative irradiation of corneal grafts. Its possible effect on the immunological reaction.","volume":"2","author":"Ainslie","year":"1961","journal-title":"Lancet"},{"key":"R65-19-20210227","first-page":"132","article-title":"Results using the strontium-90 beta-ray applicator on eye lesions.","volume":"17","author":"Duggan","year":"1966","journal-title":"J Can Assoc Radiol"},{"key":"R66-19-20210227","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bjo.45.5.358","article-title":"Treatment of non-malignant corneal conditions with radioactive isotopes: a 5-year survery.","volume":"45","author":"Faser","year":"1961","journal-title":"Br J Ophthalmol"},{"key":"R67-19-20210227","first-page":"25","article-title":"An evaluation of the clinical use of strontium 90 beta-ray applicator with a review of the underlying principles.","volume":"71","author":"Freidell","year":"1954","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"R68-19-20210227","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9394(60)92660-X","article-title":"Beta radiation in ophthalmology.","volume":"49","author":"Leahy","year":"1960","journal-title":"Am J Ophthalmol"},{"key":"R69-19-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bjo.41.1.1","article-title":"Radiotherapy of non-malignant diseases of the eye.","volume":"41","author":"Lederman","year":"1957","journal-title":"Br J Ophthalmol"},{"key":"R70-19-20210227","first-page":"1149","article-title":"Treating non-malignant corneal conditions by radiotherapy.","volume":"70","author":"Naunton","year":"1974","journal-title":"Nurs Times"},{"key":"R71-19-20210227","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.eye.6700306","article-title":"Beta radiation: new uses for an old treatment: a review.","volume":"17","author":"Kirwan","year":"2003","journal-title":"Eye"},{"key":"R72-19-20210227","first-page":"113","article-title":"Long-term complications of beta-radiation therapy in ophthalmology.","volume":"68","author":"Barron","year":"1970","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R73-19-20210227","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clae.2007.03.002","article-title":"The long-term effects of experimental beta-radiation therapy on the human cornea.","volume":"30","author":"McMahon","year":"2007","journal-title":"Con Lens Anterior Eye"},{"key":"R74-19-20210227","first-page":"655","article-title":"Clinical and experimental experiences with beta irradiation of the eye.","volume":"LVI","author":"Wilson","year":"1959","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R75-19-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/02713689508999908","article-title":"Steroid inhibition of limbal blood and lymphatic vascular cell growth.","volume":"14","author":"Boneham","year":"1995","journal-title":"Curr Eye Res"},{"key":"R76-19-20210227","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularization by bevacizumab (Avastin).","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R77-19-20210227","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3181\/00379727-74-17822","article-title":"Inhibition of vascularization of the rabbit cornea by local application of cortisone.","volume":"74","author":"Jones","year":"1950","journal-title":"Proc Soc Exp Biol Med"},{"key":"R78-19-20210227","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/archopht.1953.00920020410004","article-title":"Hydrocortisone (compound F) in ophthalmology; clinical and experimental studies.","volume":"49","author":"Mcdonald","year":"1953","journal-title":"AMA Arch Ophthalmol"},{"key":"R79-19-20210227","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archopht.1954.00920050079009","article-title":"Influence of low-voltage x-radiation on inhibition and prevention of new vessels in cornea; comparison with influence of cortisone.","volume":"52","author":"Michaelson","year":"1954","journal-title":"AMA Arch Ophthalmol"},{"key":"R80-19-20210227","first-page":"105","article-title":"The influence of cortisone on corneal vascularization in the guinea pig and rabbit.","volume":"72","author":"Wybar","year":"1952","journal-title":"Trans Ophthalmol Soc UK"},{"key":"R81-19-20210227","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9394(66)92199-4","article-title":"Experimental corneal vacularization and its management.","volume":"62","author":"Ahuja","year":"1966","journal-title":"Am J Ophthalmol"},{"key":"R82-19-20210227","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/02713688508999984","article-title":"Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea.","volume":"4","author":"Mahoney","year":"1985","journal-title":"Curr Eye Res"},{"key":"R83-19-20210227","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2353\/ajpath.2007.070172","article-title":"Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis.","volume":"171","author":"Nakao","year":"2007","journal-title":"Am J Pathol"},{"key":"R84-19-20210227","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/archopht.1983.01040010640024","article-title":"Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization.","volume":"101","author":"Phillips","year":"1983","journal-title":"Arch Ophthalmol"},{"key":"R85-19-20210227","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1001\/archopht.1985.01050020136037","article-title":"The histopathology of corneal neovascularization. Inhibitor effects.","volume":"103","author":"Robin","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"R86-19-20210227","first-page":"707","article-title":"The inhibition of prostaglandin E1-induced corneal neovascularization by steroid eye drops.","volume":"88","author":"Chang","year":"1989","journal-title":"J Formos Med Assoc"},{"key":"R87-19-20210227","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1001\/archopht.1977.04450100168024","article-title":"Endocrine influences on ulceration and regeneration in the alkali-burned cornea.","volume":"95","author":"Crabb","year":"1977","journal-title":"Arch Ophthalmol"},{"key":"R88-19-20210227","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archopht.1980.01020030516018","article-title":"Treatment of experimental herpetic interstitial keratitis with medroxyprogesterone.","volume":"98","author":"Lass","year":"1980","journal-title":"Arch Ophthalmol"},{"key":"R89-19-20210227","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clae.2008.06.009","article-title":"Subconjunctival triamcinolone for the treatment of corneal graft rejection and new vessels.","volume":"32","author":"Athanasiadis","year":"2009","journal-title":"Cont Lens Anterior Eye"},{"key":"R90-19-20210227","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/ICO.0b013e3181605ff9","article-title":"Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline.","volume":"27","author":"Aydin","year":"2008","journal-title":"Cornea"},{"key":"R91-19-20210227","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1167\/iovs.05-1651","article-title":"Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors.","volume":"47","author":"Ebrabem","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R92-19-20210227","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00417-005-0036-1","article-title":"Inhibitory effect of triamcinolone acetonide on corneal neovascularization.","volume":"244","author":"Murata","year":"2006","journal-title":"Graefes Arch Clin Ophthalmol"},{"key":"R93-19-20210227","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.ico.0000220768.11778.60","article-title":"Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model.","volume":"25","author":"Riazi-Esfahani","year":"2006","journal-title":"Cornea"},{"key":"R94-19-20210227","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0002-9394(51)91481-X","article-title":"Local and systemic cortisone in ocular disease.","volume":"34","author":"Leopold","year":"1951","journal-title":"Am J Ophthalmol"},{"key":"R96-19-20210227","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Anti-inflammatory action of glucocorticoidsnew mechanisms for old drugs.","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"key":"R97-19-20210227","first-page":"531","article-title":"An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal vascularization. II. Studies on the effect of leukocytic elimination on corneal vascularization.","volume":"81","author":"Fromer","year":"1975","journal-title":"Am J Pathol"},{"key":"R98-19-20210227","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0022-3565(25)22251-0","article-title":"An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils.","volume":"250","author":"Schleimer","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"R99-19-20210227","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/jop.1999.15.413","article-title":"Angiostatic activity of steroids in the chick embryo CAM and the rabbit cornea models of neovascularization.","volume":"15","author":"McNatt","year":"1999","journal-title":"J Ocul Pharmacol Ther"},{"key":"R100-19-20210227","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1126\/science.3014662","article-title":"Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones.","volume":"233","author":"Besedovsky","year":"1986","journal-title":"Science"},{"key":"R101-19-20210227","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1126\/science.3754653","article-title":"Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.","volume":"232","author":"Beutler","year":"1986","journal-title":"Science"},{"key":"R102-19-20210227","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/j.1476-5381.1996.tb15578.x","article-title":"Differential effects of angiostatic steroids and dexamethasone on angiogenesis and cytokine levels in rat sponge implants.","volume":"118","author":"Hori","year":"1996","journal-title":"Br J Pharmacol"},{"key":"R103-19-20210227","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.4049\/jimmunol.129.5.1803","article-title":"Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production.","volume":"129","author":"Snyder","year":"1982","journal-title":"J Immunol"},{"key":"R104-19-20210227","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/eji.1830201112","article-title":"Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts.","volume":"20","author":"Waage","year":"1990","journal-title":"Eur J Immunol"},{"key":"R105-19-20210227","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0031-6989(81)80027-6","article-title":"Hydrocortisone inhibits platelet prostaglandin and endothelial prostacyclin production.","volume":"13","author":"Jorgensen","year":"1981","journal-title":"Pharmacol Res Commun"},{"key":"R106-19-20210227","first-page":"763","article-title":"The effect of adrenal glucocorticosteroids upon the cellular composition of inflammatory exudates.","volume":"44","author":"Boggs","year":"1964","journal-title":"Am J Pathol"},{"key":"R107-19-20210227","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.me.18.020167.000525","article-title":"The role of lysosomes in inflammation and disease.","volume":"18","author":"Weissmann","year":"1967","journal-title":"Annu Rev Med"},{"key":"R108-19-20210227","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1056\/NEJM197208242870806","article-title":"Corticosteroids and lymphoid cells.","volume":"287","author":"Claman","year":"1972","journal-title":"N Engl J Med"},{"key":"R109-19-20210227","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1126\/science.2467380","article-title":"Control of angiogenesis with synthetic heparin substitutes.","volume":"243","author":"Folkman","year":"1989","journal-title":"Science"},{"key":"R110-19-20210227","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/jop.1994.10.273","article-title":"Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization.","volume":"10","author":"Lepri","year":"1994","journal-title":"J Ocul Pharmacol"},{"key":"R111-19-20210227","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1755-3768.1987.tb02600.x","article-title":"Cortisone, heparin and argon laser in the treatment of corneal neovascularization.","volume":"182","author":"Tommila","year":"1987","journal-title":"Acta Ophthalmol Suppl"},{"key":"R112-19-20210227","first-page":"2898","article-title":"Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization.","volume":"32","author":"Li","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R113-19-20210227","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/A:1006482120049","article-title":"Local antiangiogenic brain tumor therapies.","volume":"50","author":"Sipos","year":"2000","journal-title":"J Neurooncol"},{"key":"R114-19-20210227","first-page":"445","article-title":"The mode of action of antiangiogenic steroid and heparin.","volume":"61","author":"Harada","year":"1992","journal-title":"EXS"},{"key":"R115-19-20210227","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1210\/endo-119-4-1768","article-title":"A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution.","volume":"119","author":"Ingber","year":"1986","journal-title":"Endocrinology"},{"key":"R116-19-20210227","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jcp.1041550315","article-title":"Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis.","volume":"155","author":"Blei","year":"1993","journal-title":"J Cell Physiol"},{"key":"R117-19-20210227","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0161-6420(86)33581-4","article-title":"Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty.","volume":"93","author":"Nirankari","year":"1986","journal-title":"Ophthalmology"},{"key":"R118-19-20210227","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0002-9394(78)90289-1","article-title":"Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants.","volume":"86","author":"BenEzra","year":"1978","journal-title":"Am J Ophthalmol"},{"key":"R119-19-20210227","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/bjo.68.9.656","article-title":"Topical indomethacin effect on neovascularization of the cornea and on prostaglandin E2 levels.","volume":"68","author":"Frucht","year":"1984","journal-title":"Br J Ophthalmol"},{"key":"R120-19-20210227","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0952-3278(97)90546-9","article-title":"Involvement of prostaglandin E2 in rabbit corneal injury by anterior segment ischaemia.","volume":"57","author":"Ueda","year":"1997","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"R121-19-20210227","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0002-9394(79)90245-9","article-title":"Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas.","volume":"87","author":"Deutsch","year":"1979","journal-title":"Am J Ophthalmol"},{"key":"R122-19-20210227","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1167\/iovs.02-0346","article-title":"Topical nepafenac inhibits ocular neovascularization.","volume":"44","author":"Takahashi","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R123-19-20210227","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1749-6632.1999.tb08726.x","article-title":"COX-2 inhibitors. A new class of antiangiogenic agents.","volume":"889","author":"Masferrer","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"R124-19-20210227","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1076\/ceyr.19.4.300.5301","article-title":"The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat.","volume":"19","author":"Yamada","year":"1999","journal-title":"Curr Eye Res"},{"key":"R125-19-20210227","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.exer.2004.04.008","article-title":"Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization.","volume":"79","author":"Castro","year":"2004","journal-title":"Exp Eye Res"},{"key":"R126-19-20210227","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0002-9394(14)77376-3","article-title":"Flurbiprofen in the treatment of corneal neovascularization induced by contact lenses.","volume":"93","author":"Duffin","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"R127-19-20210227","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00003226-198401000-00012","article-title":"Inhibition of contact lens-induced corneal neovascularization in radial keratotomized rabbit eyes.","volume":"3","author":"Katz","year":"1984","journal-title":"Cornea"},{"key":"R128-19-20210227","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.ico.0000220767.73660.3a","article-title":"The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization.","volume":"25","author":"Peyman","year":"2006","journal-title":"Cornea"},{"key":"R129-19-20210227","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/02713688609020056","article-title":"Effect of indomethacin on immunogenic keratitis.","volume":"5","author":"van Haeringen","year":"1986","journal-title":"Curr Eye Res"},{"key":"R130-19-20210227","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/02713688809031785","article-title":"Modulators of immunogenic keratitis in rabbits by topical administration of inhibitors of lipoxygenase and cycloxygenase.","volume":"7","author":"Verby","year":"1988","journal-title":"Curr Eye Res"},{"key":"R131-19-20210227","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-4835(92)90108-5","article-title":"Inhibition of corneal neovascularization in the rat by SKF 86002, a dual inhibitor of arachadoic acid metabolism.","volume":"55","author":"Haynes","year":"1992","journal-title":"Exp Eye Res"},{"key":"R132-19-20210227","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0886-3350(01)00801-X","article-title":"Corneal complications associated with topical ophthalmic use of nonsteroidal anti-inflammatory drugs.","volume":"27","author":"Congdon","year":"2001","journal-title":"J Cataract Refract Surg"},{"key":"R134-19-20210227","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0161-6420(00)00538-8","article-title":"Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs.","volume":"108","author":"Guidera","year":"2001","journal-title":"Ophthalmology"},{"key":"R135-19-20210227","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R136-19-20210227","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/ICU.0b013e3282f0ca54","article-title":"Anti-vascular endothelial growth factor therapy for ocular neovascular disease.","volume":"18","author":"Andreoli","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"key":"R137-19-20210227","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00003226-200007000-00025","article-title":"Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization.","volume":"19","author":"Cursiefen","year":"2000","journal-title":"Cornea"},{"key":"R138-19-20210227","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-0420.2004.00312.x","article-title":"Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovasculairzation and wound healing.","volume":"82","author":"Gan","year":"2004","journal-title":"Acta Ophthalmol Scand"},{"key":"R139-19-20210227","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1442-9071.2007.01572.x","article-title":"Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.","volume":"35","author":"Hosseini","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"key":"R140-19-20210227","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1167\/iovs.01-1277","article-title":"VEGF-dependent conjunctivalization of the corneal surface.","volume":"44","author":"Joussen","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R141-19-20210227","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/S0002-9440(10)63267-1","article-title":"Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes. Therpeutic strategy for herpetic stromal keratitis.","volume":"165","author":"Kim","year":"2004","journal-title":"Am J Pathol"},{"key":"R142-19-20210227","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1006\/exer.2002.2075","article-title":"Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA.","volume":"75","author":"Lai","year":"2002","journal-title":"Exp Eye Res"},{"key":"R143-19-20210227","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/02713680500514636","article-title":"Inhibition of ocular angiogenesis by diced small interfering RNAs (siRNAs) specific to vascular endothelial growth factor (VEGF).","volume":"31","author":"Murata","year":"2006","journal-title":"Curr Eye Res"},{"key":"R144-19-20210227","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R145-19-20210227","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1167\/iovs.04-1172","article-title":"Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo.","volume":"46","author":"Singh","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R146-19-20210227","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R147-19-20210227","first-page":"233","article-title":"Vascular permeability factor\/vascular endothelial growth factor: a multifunctional angiogenic cytokine.","volume":"79","author":"Brown","year":"1997","journal-title":"EXS"},{"key":"R148-19-20210227","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors.","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"R149-19-20210227","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/373573a0","article-title":"Protein modules and signalling networks.","volume":"373","author":"Pawson","year":"1995","journal-title":"Nature"},{"key":"R150-19-20210227","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1038\/sj.onc.1202527","article-title":"VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells.","volume":"18","author":"Takahashi","year":"1999","journal-title":"Oncogene"},{"key":"R151-19-20210227","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1677\/erc.0.0080161","article-title":"Receptor tyrosine kinase signalling as a target for cancer intervention strategies.","volume":"8","author":"Zwick","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"R152-19-20210227","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"R153-19-20210227","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/dji003","article-title":"Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.","volume":"97","author":"Pytowski","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R154-19-20210227","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1006094117427","article-title":"Monoclonal antibodies targeting the VEGF receptor-2 (Flk1\/KDR) as an anti-angiogenic therapeutic strategy.","volume":"17","author":"Witte","year":"1998","journal-title":"Cancer Metastasis Rev"},{"key":"R155-19-20210227","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.","volume":"92","author":"Aiello","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R156-19-20210227","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/ICO.0b013e31802b4201","article-title":"Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization.","volume":"26","author":"Singh","year":"2007","journal-title":"Cornea"},{"key":"R157-19-20210227","first-page":"99","article-title":"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.","volume":"59","author":"Fong","year":"1999","journal-title":"Cancer Res"},{"key":"R158-19-20210227","first-page":"3540","article-title":"Flk-1 as a target for tumor growth inhibition.","volume":"56","author":"Strawn","year":"1996","journal-title":"Cancer Res"},{"key":"R159-19-20210227","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/00007890-199812150-00016","article-title":"Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat.","volume":"66","author":"Yatoh","year":"1998","journal-title":"Transplantation"},{"key":"R160-19-20210227","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","article-title":"Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.","volume":"45","author":"Cursiefen","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R161-19-20210227","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archopht.126.1.71","article-title":"Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation.","volume":"126","author":"Bachmann","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R162-19-20210227","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1590\/S0001-37652007000300004","article-title":"The effects of subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea.","volume":"79","author":"Barros","year":"2007","journal-title":"An Acad Bras Cienc"},{"key":"R163-19-20210227","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1167\/iovs.08-1997","article-title":"Subconjuncitval injection of bevacizumab (Avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.","volume":"50","author":"Chen","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R164-19-20210227","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1755-3768.2009.01571.x","article-title":"The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.","volume":"88","author":"Habot-Wilner","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R165-19-20210227","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00417-008-0976-3","article-title":"Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.","volume":"247","author":"Han","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R166-19-20210227","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000224783","article-title":"Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.","volume":"42","author":"Hashemian","year":"2009","journal-title":"Ophthalmic Res"},{"key":"R167-19-20210227","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.mehy.2006.06.063","article-title":"A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents.","volume":"68","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"R168-19-20210227","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/ICO.0b013e318160d019","article-title":"Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.","volume":"27","author":"Hurmeric","year":"2008","journal-title":"Cornea"},{"key":"R169-19-20210227","first-page":"1955","article-title":"-L, Gao X.-W, Ren B, et al. The inhibitory action of bevacizumab on rat corneal neovascularization.","volume":"8","author":"Jing","year":"2008","journal-title":"Int J Ophthalmol"},{"key":"R170-19-20210227","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ICO.0b013e31815cf67d","article-title":"Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).","volume":"27","author":"Kim","year":"2008","journal-title":"Cornea"},{"key":"R171-19-20210227","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/02713680802607740","article-title":"The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas.","volume":"34","author":"Oh","year":"2009","journal-title":"Curr Eye Res"},{"key":"R172-19-20210227","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":"Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R173-19-20210227","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","article-title":"Safety profile of bevacizumab on cultured human corneal cells.","volume":"26","author":"Yoeruek","year":"2007","journal-title":"Cornea"},{"key":"R174-19-20210227","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","article-title":"Tubingen Bevacizumab Study Group. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.","volume":"86","author":"Yoeruek","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R175-19-20210227","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.jcrs.2007.07.012","article-title":"Subconjunctival bevacizumab for vascularized rejected corneal grafts.","volume":"33","author":"Awadein","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"R176-19-20210227","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.","volume":"33","author":"Bahar","year":"2008","journal-title":"Curr Eye Res"},{"key":"R177-19-20210227","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"R178-19-20210227","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.ico.0000611440.32234.8f","article-title":"Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis.","volume":"27","author":"Carrasco","year":"2008","journal-title":"Cornea"},{"key":"R179-19-20210227","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, non-comparative study.","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R180-19-20210227","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization.","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R181-19-20210227","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"27","author":"Doctor","year":"2008","journal-title":"Cornea"},{"key":"R182-19-20210227","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R183-19-20210227","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/ICO.0b013e318180e50f","article-title":"Bevacizumab (Avastin) and argon laser to treat neovascularization in corneal transplant surgery.","volume":"27","author":"Gerten","year":"2008","journal-title":"Cornea"},{"key":"R184-19-20210227","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.ophtha.2007.05.016","article-title":"Bevacizumab for graft rejection.","volume":"114","author":"Harooni","year":"2007","journal-title":"Ophthalmology"},{"key":"R186-19-20210227","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization.","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"R187-19-20210227","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/ICO.0b013e3181861cc9","article-title":"Bevacizumab (Avastin) for corneal neovascularization-corneal light shield soaked application.","volume":"28","author":"Mackenzie","year":"2009","journal-title":"Cornea"},{"key":"R188-19-20210227","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/ICO.0b013e31817c41e3","article-title":"Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Qian","year":"2008","journal-title":"Cornea"},{"key":"R189-19-20210227","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/ICO.0b013e318158f6ad","article-title":"Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome.","volume":"27","author":"Uy","year":"2008","journal-title":"Cornea"},{"key":"R190-19-20210227","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","article-title":"Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R191-19-20210227","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1442-9071.2007.01616.x","article-title":"Are we getting closer to prevention and treatment of corneal neovascularization?","volume":"35","author":"Chevez-Barrios","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"key":"R192-19-20210227","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"R193-19-20210227","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":"Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.","volume":"168","author":"Jo","year":"2006","journal-title":"Am J Pathol"},{"issue":"Suppl 1","key":"R194-19-20210227","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.9-suppl_1-11","article-title":"Targeted therapy of colorectal cancer: clinical experience with bevacimuzab.","volume":"9","author":"Fernando","year":"2004","journal-title":"Oncologist"},{"key":"R195-19-20210227","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacimuzab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer.","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"R196-19-20210227","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R198-19-20210227","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s004170050257","article-title":"Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study.","volume":"237","author":"Heiligenhaus","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R199-19-20210227","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archopht.1992.01080150103037","article-title":"Suppression of corneal neovascularization with cyclosporine.","volume":"110","author":"Lipman","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"R200-19-20210227","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S0161-6420(89)32756-4","article-title":"Topical cyclosporine in high-risk corneal transplants.","volume":"96","author":"Belin","year":"1989","journal-title":"Ophthalmology"},{"key":"R201-19-20210227","first-page":"274","article-title":"Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A.","volume":"38","author":"Benelli","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R202-19-20210227","first-page":"1461","article-title":"Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats.","volume":"12","author":"Bourges","year":"2006","journal-title":"Mol Vis"},{"key":"R203-19-20210227","first-page":"212","article-title":"Penetrating keratoplasty in the rat: a model for the study of immunosuppressive treatment of graft rejection.","volume":"33","author":"Herbort","year":"1989","journal-title":"Jpn J Ophthalmol"},{"key":"R204-19-20210227","first-page":"173","article-title":"Cyclosporin-A applied topically to the recipient eye inhibits corneal graft rejection.","volume":"45","author":"Hunter","year":"1981","journal-title":"Clin Exp Immunol"},{"key":"R205-19-20210227","first-page":"686","article-title":"Rabbit corneal allograft survival following administration of cyclosporin-A.","volume":"22","author":"Kana","year":"1982","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R206-19-20210227","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00003226-199407000-00007","article-title":"Mixed lymphocyte culture responses in rabbits undergoing corneal grafting and topical cyclosporine treatment.","volume":"13","author":"Maske","year":"1994","journal-title":"Cornea"},{"key":"R207-19-20210227","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1442-9071.2008.01784.x","article-title":"Topical cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial.","volume":"36","author":"Poon","year":"2008","journal-title":"Clin Experiment Ophthalmol"},{"key":"R208-19-20210227","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00003226-199409000-00013","article-title":"Suppression of corneal allograft rejection by systemic cyclosporine-A in heavily vascularized rabbit corneas following alkali burns.","volume":"13","author":"Rehany","year":"1994","journal-title":"Cornea"},{"key":"R209-19-20210227","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1981.03930020514024","article-title":"Suppression of corneal allograft rejection by cyclosporin A.","volume":"99","author":"Salisbury","year":"1981","journal-title":"Arch Ophthalmol"},{"key":"R210-19-20210227","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00007890-198503000-00004","article-title":"A comparison of the effects of topical cyclosporine and topical steroid on rabbit corneal graft rejection.","volume":"39","author":"Williams","year":"1985","journal-title":"Transplant"},{"key":"R211-19-20210227","first-page":"595","article-title":"Laser photocoagulation for corneal stromal vascularization.","volume":"90","author":"Nirankari","year":"1992","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R212-19-20210227","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9394(00)00625-5","article-title":"Unusual corneal deposit after the topical use of cyclosporine as eyedrops.","volume":"130","author":"Kachi","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"R213-19-20210227","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10792-007-9180-4","article-title":"Regression of severe corneal stromal neovascularization with topical cyclosporine 0.05% after penetrating keratoplasty for fungal corneal ulcer.","volume":"29","author":"Sonmez","year":"2009","journal-title":"Int Ophthalmol"},{"key":"R214-19-20210227","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0014-4835(03)00030-7","article-title":"Recent developments in ocular gene therapy.","volume":"76","author":"Borras","year":"2003","journal-title":"Exp Eye Res"},{"key":"R215-19-20210227","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1164\/ajrccm.162.supplement_3.15tac11","article-title":"Gene delivery to the corneal endothelium.","volume":"162","author":"George","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"R216-19-20210227","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/sj.eye.6700565","article-title":"Prospects for gene therapy in corneal disease.","volume":"17","author":"Jun","year":"2003","journal-title":"Eye"},{"key":"R217-19-20210227","first-page":"1334","article-title":"Ocular gene therapy: a review of non-viral strategies.","volume":"12","author":"Soler-Andrieu","year":"2006","journal-title":"Mol Vis"},{"key":"R218-19-20210227","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1517\/14712598.4.7.1059","article-title":"Gene therapy approaches to prolonging corneal allograft survival.","volume":"4","author":"Williams","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"R219-19-20210227","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/427779a","article-title":"The future of gene therapy.","volume":"427","author":"Cavazzano-Calvo","year":"2004","journal-title":"Nature"},{"key":"R220-19-20210227","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N Engl J Med"},{"key":"R221-19-20210227","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1126\/science.286.5448.2244","article-title":"Gene therapy death prompts a review of adenovirus vector.","volume":"286","author":"Marshall","year":"1999","journal-title":"Science"},{"key":"R222-19-20210227","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ymthe.2004.09.022","article-title":"Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain.","volume":"11","author":"Provost","year":"2005","journal-title":"Mol Ther"},{"key":"R223-19-20210227","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/ncb1038","article-title":"Activation of the interferon system by short-interfering RNAs.","volume":"5","author":"Sledz","year":"2003","journal-title":"Nat Cell Biol"},{"issue":"pt 6","key":"R224-19-20210227","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1042\/BST0320952","article-title":"RNA interference and double-stranded-RNA-activated pathways.","volume":"32","author":"Sledz","year":"2004","journal-title":"Biochem Soc Trans"},{"key":"R225-19-20210227","first-page":"523","article-title":"Corneal argon laser photocoagulation for the treatment of stromal neovascularization.","volume":"38","author":"Baer","year":"1987","journal-title":"Surg Forum"},{"key":"R226-19-20210227","first-page":"911","article-title":"Argon laser treatment of corneal neovascularization.","volume":"5","author":"Cherry","year":"1973","journal-title":"Ann Ophthalmol"},{"key":"R227-19-20210227","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/00003226-200211000-00007","article-title":"Fluorescein-potentiated argon laser therapy improves symptoms and appearance of corneal neovascularization.","volume":"21","author":"Jerold Gordon","year":"2002","journal-title":"Cornea"},{"key":"R228-19-20210227","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3341\/kjo.1993.7.1.25","article-title":"Treatment of corneal neovascularization with argon laser.","volume":"7","author":"Lim","year":"1993","journal-title":"Korean J Ophthalmol"},{"key":"R229-19-20210227","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/bjo.66.2.127","article-title":"Treatment of lipid keratopathy with the argon laser.","volume":"66","author":"Marsh","year":"1982","journal-title":"Br J Ophthalmol"},{"key":"R230-19-20210227","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/bjo.72.12.900","article-title":"Argon laser treatment of lipid keratopathy.","volume":"72","author":"Marsh","year":"1988","journal-title":"Br J Ophthalmol"},{"issue":"pt 1","key":"R231-19-20210227","first-page":"154","article-title":"Lasering of lipid keratopathy.","volume":"102","author":"Marsh","year":"1982","journal-title":"Trans Ophthalmol Soc U K"},{"key":"R232-19-20210227","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1442-9071.2004.00764.x","article-title":"Fluorescein angiographic monitoring of corneal vascularization in lipid keratopathy.","volume":"32","author":"Peter","year":"2004","journal-title":"Clin Exp Ophthalmol"},{"key":"R233-19-20210227","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ajo.2005.11.003","article-title":"Argon laser photodynamic therapy of human corneal neovascularization after intravenous administration of dihematoporphyrin ether.","volume":"141","author":"Sheppard","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R234-19-20210227","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0161-6420(92)31754-3","article-title":"Laser treatment of corneal vessels.","volume":"99","author":"Staffileno","year":"1999","journal-title":"Ophthalmology"},{"key":"R235-19-20210227","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/bjo.60.6.464","article-title":"Corneal neovascularization treated with argon laser.","volume":"60","author":"Cherry","year":"1976","journal-title":"Br J Ophthalmol"},{"key":"R236-19-20210227","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00003226-198706040-00004","article-title":"Corneal neovascularization: pathogenesis and inhibition.","volume":"6","author":"Epstein","year":"1987","journal-title":"Cornea"},{"key":"R237-19-20210227","first-page":"50","article-title":"Necrotizing scleritis following laser therapy for corneal vascularization.","volume":"41","author":"Pai","year":"2009","journal-title":"Ann Ophthalmol"},{"key":"R238-19-20210227","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0161-6420(92)31996-7","article-title":"Corneal laser photocoagulation for treatment of neovascularization. Efficacy of 577 nm yellow dye laser.","volume":"99","author":"Baer","year":"1992","journal-title":"Ophthalmology"},{"key":"R239-19-20210227","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/lsm.1900050406","article-title":"Retinal effects of frequecny doubled nd:YAG (532 nm) laser: histopathological comparision with argon laser.","volume":"5","author":"Mosier","year":"1985","journal-title":"Laser Surg Med"},{"key":"R240-19-20210227","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00003226-199305000-00001","article-title":"Biomicroscopic and histopathologic observations after corneal laser photocoagulation in a rabbit model of corneal neovascularization.","volume":"12","author":"Hemady","year":"1993","journal-title":"Cornea"},{"key":"R241-19-20210227","first-page":"235","article-title":"Frequency doubled Nd:YAG (532 nm) laser photocoagulation in corneal vascularization: efficacy and time sequenced changes.","volume":"49","author":"Sharma","year":"2001","journal-title":"Indian J Ophthalmol"},{"key":"R242-19-20210227","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00003226-199405000-00013","article-title":"Hemorrhage complicating YAG laser feeder vessel coagulation of cornea vascularization.","volume":"13","author":"Parsa","year":"1994","journal-title":"Cornea"},{"key":"R243-19-20210227","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3928\/1081-597X-19950101-12","article-title":"Comparison of yellow dye, continuous wave Nd:YAG, and argon green laser on experimentally induced corneal neovascularization.","volume":"11","author":"Krasnick","year":"1995","journal-title":"J Refract Surg"},{"key":"R244-19-20210227","first-page":"291","article-title":"Q-switched Nd:YAG laser treatment for corneal neovascularization.","volume":"36","author":"Goto","year":"1992","journal-title":"Jpn J Ophthalmol"},{"key":"R245-19-20210227","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/lsm.1900080503","article-title":"Molecular, cellular, and tissue responses following photodynamic therapy.","volume":"8","author":"Gomer","year":"1988","journal-title":"Laser Surg Med"},{"key":"R246-19-20210227","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1751-1097.1992.tb04222.x","article-title":"How does photodynamic therapy work?","volume":"55","author":"Henderson","year":"1992","journal-title":"Photochem Photobiol"},{"key":"R247-19-20210227","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.ico.0000178731.42187.46","article-title":"Prevention and treatment of corneal graft rejection: current practice patterns.","volume":"25","author":"Randleman","year":"2006","journal-title":"Cornea"},{"key":"R248-19-20210227","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0022-4804(88)90195-3","article-title":"The effect of photodynamic therapy on the microcirculation.","volume":"45","author":"Reed","year":"1988","journal-title":"J Surg Res"},{"key":"R249-19-20210227","first-page":"223","article-title":"Zypen E van der. Basic mechanisms underlying laser throbogenesis in the vascular structures of the eye.","volume":"2","author":"Fankhauser","year":"1989","journal-title":"Laser Light Ophthalmol"},{"key":"R250-19-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1011-1344(96)07428-3","article-title":"Photophysical and photobiological processes in the photodynamic therapy of tumours.","volume":"39","author":"Ochsner","year":"1997","journal-title":"J Photochem Photobiol"},{"key":"R251-19-20210227","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/bjo.2003.035071","article-title":"Photodynamic therapy for corneal neovascularization and lipid degeneration.","volume":"88","author":"Brooks","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"R252-19-20210227","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00003226-200307000-00018","article-title":"Photodynamic therapy of corneal neovascularization with verteporfin.","volume":"22","author":"Fossarello","year":"2003","journal-title":"Cornea"},{"key":"R253-19-20210227","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ajo.2007.05.028","article-title":"Photodynamic therapy with verteporfin for corneal neovascularization.","volume":"144","author":"Yoon","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R254-19-20210227","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/00003226-200211000-00007","article-title":"Fluorescein-potentiated argon laser therapy improves symptoms and appearance of corneal neovascularization.","volume":"21","author":"Gordon","year":"2002","journal-title":"Cornea"},{"key":"R256-19-20210227","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archopht.1989.01070020575043","article-title":"Promotion of graft survival by photothrombotic occlusion of corneal neovascularization.","volume":"107","author":"Corrent","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"R257-19-20210227","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trial-TAP report.","volume":"117","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"R258-19-20210227","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.ico.0000248383.09272.ee","article-title":"Electrolysis-needle cauterization of corneal vessels in patients with lipid keratopathy.","volume":"26","author":"Wertheim","year":"2007","journal-title":"Cornea"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003226-201108000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T22:41:47Z","timestamp":1741041707000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201108000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":251,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e318201405a","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}